Aegle Therapeutics products

Advancement of extracellular vesicle therapy to the patient has been hampered by an inability to isolate extracellular vesicles in useful quantities while preserving their structural and functional integrity. EVs derived from MSCs enjoy the same immunosuppressant characteristics of their parent cells. However, when EVs are processed incorrectly, they can trigger an adverse inflammation response in vivo. The ability to properly isolate EVs from cells is critical to the success of extracellular vesicle therapy.

Thermal injury is one of the most common and devastating forms of trauma, as it affects the skin, the largest and most visible organ. According to the CDC, about 1.1 million people suffer a burn injury and seek medical help every year in the U.S. Of those, approximately 50,000 suffer moderate to severe burns and require hospitalization for treatment for days or even months with 20,000 suffering burns over 25% of their total body surface area (“TBSA”). The American Burn Association (“ABA”) estimates that approximately 3,400 deaths are attributable to burn injuries.

Aegle’s founder Dr. Evangelos Badiavas and his team have spent decades researching clinical applications of mesenchymal stem cells (“MSCs”) in severe dermatological disorders, including conducting clinical trials in burns and wounds under multiple INDs. In these trials, patients experienced accelerated healing, little to no scarring, total wound closure and tissue regeneration. However, given that MSCs are hard to predict and control in vivo, compounded by the high costs of production, Dr. Badiavas and his team set out to discover ways to harness the healing power of stem cells without using the cells.

Epidermolysis bullosa (“EB”) is a group of rare genetic disorders that manifests as blistering or erosion of the skin in response to little or no apparent trauma. There are many genetic and symptomatic variations of EB. EB is always painful, often pervasive and debilitating, and is in some cases lethal before the age of 30. EB affects both genders and every racial and ethnic background equally. The most severe forms of EB require meticulous care similar to that given to burn patients. Standard treatment for EB patients is daily wound care, bandaging and pain management. There is no treatment or cure for EB.